ES2191180T3 - Antagonistas de los receptores de la dopamina benzoxazinona d4. - Google Patents

Antagonistas de los receptores de la dopamina benzoxazinona d4.

Info

Publication number
ES2191180T3
ES2191180T3 ES97925651T ES97925651T ES2191180T3 ES 2191180 T3 ES2191180 T3 ES 2191180T3 ES 97925651 T ES97925651 T ES 97925651T ES 97925651 T ES97925651 T ES 97925651T ES 2191180 T3 ES2191180 T3 ES 2191180T3
Authority
ES
Spain
Prior art keywords
antagonists
benzoxazinona
dopamine receptors
naftilo
rent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97925651T
Other languages
English (en)
Inventor
Thomas Belliotti
Lawrence David Wise
David Juergen Wustrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2191180T3 publication Critical patent/ES2191180T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LOS COMPUESTOS DE FORMULAS (I) O (II) EN LAS QUE R 1 Y R 2 SON, INDEPENDIENTEMENTE, HIDROGENO O ALQUILO C 1 C 6 ; X ES N O CH; Y R 3 ES FENILO, NAFTILO, HETER OARILO, FENILO SUSTITUIDO, NAFTILO SUSTITUIDO O HETEROARILO SUSTITUIDO, SELECCIONANDOSE CADA SUSTITUYENTE, INDEPENDIENTEMENTE, DEL HALOGENO, ALCOXI C 1 - C 6 , ALQUILO C 1 - C 6 , - CN, - CF 3 , O SULFONAMIDO, Y LAS SALES FARMACEUTICAMENTE ACEPTABLES, ESTERES, AMIDAS Y PROFARMACOS DE LOS MISMOS SON ANTAGONISTAS DE LOS RECEPTORES DE DOPAMINA D4.
ES97925651T 1996-05-29 1997-05-20 Antagonistas de los receptores de la dopamina benzoxazinona d4. Expired - Lifetime ES2191180T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1838396P 1996-05-29 1996-05-29
US4020897P 1997-03-06 1997-03-06

Publications (1)

Publication Number Publication Date
ES2191180T3 true ES2191180T3 (es) 2003-09-01

Family

ID=26691052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97925651T Expired - Lifetime ES2191180T3 (es) 1996-05-29 1997-05-20 Antagonistas de los receptores de la dopamina benzoxazinona d4.

Country Status (36)

Country Link
EP (1) EP0906294B1 (es)
JP (1) JP2000511534A (es)
KR (1) KR20000016151A (es)
CN (1) CN1074764C (es)
AR (1) AR008372A1 (es)
AT (1) ATE231846T1 (es)
AU (1) AU731104B2 (es)
BG (1) BG64049B1 (es)
BR (1) BR9709630A (es)
CA (1) CA2253406A1 (es)
CO (1) CO4940505A1 (es)
CZ (1) CZ384698A3 (es)
DE (1) DE69718786T2 (es)
DK (1) DK0906294T3 (es)
EA (1) EA001486B1 (es)
EE (1) EE03686B1 (es)
ES (1) ES2191180T3 (es)
GE (1) GEP20012389B (es)
HN (1) HN1997000075A (es)
HR (1) HRP970301B1 (es)
HU (1) HUP9903758A3 (es)
ID (1) ID17266A (es)
IL (1) IL126895A (es)
NO (1) NO312296B1 (es)
NZ (1) NZ332737A (es)
PA (1) PA8431101A1 (es)
PE (1) PE69398A1 (es)
PL (1) PL330195A1 (es)
PT (1) PT906294E (es)
RO (1) RO120845B1 (es)
SI (1) SI0906294T1 (es)
SK (1) SK282703B6 (es)
SV (1) SV1997000047A (es)
TW (1) TW542833B (es)
UY (1) UY24569A1 (es)
WO (1) WO1997045419A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177422B1 (en) 1996-05-29 2001-01-23 Warner-Lambert Company Benzoxazinone dopamine D4 receptor antagonists
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
EP1089990A1 (en) * 1998-06-30 2001-04-11 Neurogen Corporation 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines: dopamine receptor subtype specific ligands
US6177566B1 (en) 1998-06-30 2001-01-23 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
CA2336089A1 (en) * 1998-06-30 2000-01-06 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl)benzodioxane and 6-(4-arylalkylpiperazin-1-yl)chromane derivatives: dopamine receptor subtype specific ligands
US6291463B1 (en) 1998-06-30 2001-09-18 Neurogen Corporation 1-(Benzothiazol-2-yl)-4-(1-phenylmethyl) piperazines: dopamine receptor subtype specific ligands
DE19844291A1 (de) 1998-09-18 2000-03-23 Schering Ag Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
HUP0301458A2 (hu) 2000-10-26 2003-10-28 Smithkline Beecham Plc. Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása
GB0203804D0 (en) 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
GB0209244D0 (en) * 2002-04-23 2002-06-05 Glaxo Group Ltd Compounds
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
ES2232292B1 (es) * 2003-07-30 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Compuestos sulfonamidicos derivados de benzoxazinona, su preparacion y uso como medicamentos.
CN100455573C (zh) * 2005-11-11 2009-01-28 华东理工大学 一种制备1,4-苯并噁唑嗪-3-酮化合物的微波合成方法
KR200482995Y1 (ko) 2015-08-19 2017-03-23 이현진 물 공급부를 구비하는 얼음 트레이
WO2022223025A1 (zh) * 2021-04-23 2022-10-27 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS USED AS PARP1 INHIBITORS
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613598A (en) * 1984-03-13 1986-09-23 Mitsubishi Chemical Industries Limited Piperazine derivatives and their acid addition salts
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
AU4704593A (en) * 1992-08-06 1994-03-03 Smithkline Beecham Plc 5-(2-oxyphenyl)-pyrrole derivatives as dopamine d3 receptor antagonists

Also Published As

Publication number Publication date
SV1997000047A (es) 1998-08-13
EA199800987A1 (ru) 1999-06-24
NZ332737A (en) 2000-06-23
EP0906294A1 (en) 1999-04-07
WO1997045419A1 (en) 1997-12-04
CA2253406A1 (en) 1997-12-04
NO985531L (no) 1998-11-27
TW542833B (en) 2003-07-21
SK162798A3 (en) 1999-06-11
AR008372A1 (es) 2000-01-19
HUP9903758A3 (en) 2000-07-28
UY24569A1 (es) 2001-08-27
HN1997000075A (es) 1997-07-30
ATE231846T1 (de) 2003-02-15
ID17266A (id) 1997-12-18
IL126895A (en) 2001-06-14
BG64049B1 (bg) 2003-11-28
SK282703B6 (sk) 2002-11-06
HRP970301A2 (en) 1998-04-30
CN1219930A (zh) 1999-06-16
AU731104B2 (en) 2001-03-22
EA001486B1 (ru) 2001-04-23
CZ384698A3 (cs) 1999-03-17
HRP970301B1 (en) 2002-08-31
JP2000511534A (ja) 2000-09-05
PL330195A1 (en) 1999-04-26
BR9709630A (pt) 1999-08-10
NO985531D0 (no) 1998-11-27
PE69398A1 (es) 1998-12-02
BG102959A (en) 1999-08-31
HK1019737A1 (en) 2000-02-25
AU3072797A (en) 1998-01-05
GEP20012389B (en) 2001-03-25
SI0906294T1 (en) 2003-04-30
HUP9903758A2 (hu) 2000-06-28
EP0906294B1 (en) 2003-01-29
RO120845B1 (ro) 2006-08-30
CO4940505A1 (es) 2000-07-24
PT906294E (pt) 2003-06-30
CN1074764C (zh) 2001-11-14
DE69718786T2 (de) 2003-10-23
IL126895A0 (en) 1999-09-22
DE69718786D1 (de) 2003-03-06
NO312296B1 (no) 2002-04-22
KR20000016151A (ko) 2000-03-25
EE03686B1 (et) 2002-04-15
DK0906294T3 (da) 2003-05-05
EE9800417A (et) 1999-06-15
PA8431101A1 (es) 2001-12-14

Similar Documents

Publication Publication Date Title
ES2191870T3 (es) Pirazoles parasiticidas.
MX9300842A (es) Antagonistas de endotelina de sulfonamida.
DK0804196T3 (da) Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
PA8467101A1 (es) Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orli
MX9505063A (es) Tetralina- e indano-1h-imidazoles.
ES2108700T3 (es) Derivados de diazabiciclonolilo como antagonistas del receptor 5-ht3.
ES2188584T3 (es) Derivados heterociclicos de amina.
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
MX9603845A (es) Profarmacos de antagonistas del receptor de morfolino-taquiquinina.
DE60143493D1 (de) 2-Oxo-1-Pyrrolidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
ES2188242T3 (es) Derivados de quinolina.
ES2170855T3 (es) Derivados de 1,4-benzodioxina.
ES2159749T3 (es) Derivados de bencilamino-2-metil-propanamidas 2-(4-sustituidas).
AR002690A1 (es) Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado.
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
CO4340623A1 (es) Derivados de indolina, metodo de preparacion y uso
ES2166470T3 (es) Derivados de indolalquilo de la benzodioxanmetilamina como ligandos de los receptores 5-ht1a.
ES2123873T3 (es) Pirrolocarbazol.
ES2148329T3 (es) Antagonistas del receptor de fibrinogeno.
AR025796A1 (es) Quinazolinonas
ES2154470T3 (es) Derivados de tetrahidroisoquinolina y su uso farmaceutico.
PE69398A1 (es) Antagonistas de receptor de benzoxazinona dopamina d4
ES2159017T3 (es) 2-aminoindanos como ligandos selectivos de la dopamina d3.